RPG Life Sciences Limited announces an acquisition

No. The 9 September regulatory filing does not specify how the Rs 243.33 Crores raised by RPG Active Pharma will be deployed. It only states that the subsidiary allotted 40% of its equity to the investors for total consideration of Rs 243.33 Crores and remained a subsidiary of RPG Life Sciences.^[1]

The filing does not earmark the proceeds for:

• capacity-expansion capex; or
• repayment of existing debt.

Separate media reports describe the broader investment plan as supporting manufacturing infrastructure, product-portfolio expansion, process development, and organic or inorganic growth, including acquisitions.^[3] Another report states that the recent equity raise funded RPG Active Pharma’s acquisition of Raghava Life Sciences’ API and intermediates business, for up to Rs 135 Crores.^[4] However, these reports do not provide a specific allocation of the Rs 243.33 Crores or indicate that any portion is intended for debt repayment.

Conclusion: the disclosed proceeds have a strategic growth and expansion context, but the official capital-infusion disclosure does not provide a formal use-of-proceeds schedule or confirm subsidiary-level capex versus debt repayment.

The revised ownership of RPG Active Pharma (RPGAP) is:

The filing does not provide the individual percentage split between India Life Sciences Fund IV Domestic and Vistaject Fund. The allotment consideration was Rs 243.33 Crores. ^[1]

Consolidation status: unchanged. RPGAP continues to be a subsidiary of RPG Life Sciences after the allotment, so the transaction does not convert it into an associate or a financial investment for consolidated reporting purposes. ^[1]

Accounting implication: the subsidiary would remain consolidated, but the ownership attribution changes. The consolidated financial statements should reflect the 40% outside ownership as a non-controlling interest, with the residual 60% attributable to RPG Life Sciences. This is an accounting implication of retaining subsidiary status, rather than a change in consolidation method.

The cited allotment disclosure does not set out the detailed journal entries or the precise treatment in RPG Life Sciences’ standalone financial statements. Therefore, while the consolidated status is clear, the standalone carrying-value treatment cannot be determined from this filing alone.